$ONC

BeOne Medicines to Invest $300 Million to Expand US Drug Manufacturing

BeOne Medicines (ONC) said Thursday it plans to invest $300 million to expand its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey.The expansion will advance BeOne's oncology pipeline of more than 35 clinical and commercial-stage assets, the company said.The investment will fund the construction of a new three-story, 145,000-square-foot building near BeOne's existing Hopewell facilities, increasing the total campus footprint to about 545,000 square feet, the company added.Price: $322.62, Change: $+2.69, Percent Change: +0.84%

Beone Medicines Insider Sold Shares Worth $18,256,808, According to a Recent SEC Filing

John Oyler, Director, Chief Executive Officer, on July 10, 2026, sold 60,218 shares in Beone Medicines (ONC) for $18,256,808. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,637,304 ordinary shares of the company, with 5,605,310 shares held directly and 46,031,994 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1651308/000104204726000011/xslF345X05/wk-form4_1784078719.xml

Beone Medicines Insider Sold Shares Worth $44,626,424, According to a Recent SEC Filing

John Oyler, Director, Chief Executive Officer, on July 14, 2026, sold 145,861 shares in Beone Medicines (ONC) for $44,626,424. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,477,911 ordinary shares of the company, with 5,445,917 shares held directly and 46,031,994 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1651308/000104204726000013/xslF345X05/wk-form4_1784078797.xml

Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Ahead of Key Economic Reports

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up marginally, and the actively traded Invesco QQQ Trust (QQQ) retreated 0.1% in Tuesday's premarket activity as investors looked ahead to key economic data while concluding one of the strongest quarters for US equities in years.US stock futures were trending lower, with the S&P 500 Index futures, Dow Jones Industrial Average futures, and Nasdaq futures down slightly before the start of regular trading.The Case-Shiller Home Price Index and the Federal Housing Finance Agency House Price Index, both for April, will be released at 9 am ET.The Chicago purchasing managers' index for June is slated for a 9:45 am ET release, followed by the June consumer confidence report and May Job Openings and Labor Turnover Survey at 10 am.Cleveland Fed President Beth Hammack is scheduled to speak on Tuesday.In premarket action, bitcoin was down by 1.9%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2% lower, Ether ETF (EETH) fell 2.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 2.6%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was steady, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 1%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.4%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Patrick Industries (PATK) shares were down more than 8% pre-bell, while LCI Industries (LCII) stock rose 2% after the companies said they have entered into a definitive agreement to merge in an all-stock transaction.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.6% higher.Lloyds Banking Group (LYG) shares traded up over 1% in early hours activity after Bloomberg reported that the company is planning to increase its focus on workplace pensions to boost its wealth segment as part of its five-year strategy through 2030.HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced marginally, the Vanguard Health Care Index Fund (VHT) increased 0.4%, and the iShares US Healthcare ETF (IYH) advanced by 0.9%. The iShares Biotechnology ETF (IBB) was 0.3% higher.BeOne Medicines' (ONC) stock was down slightly premarket, partially reversing the 3.6% gain at the previous close. The company said Brukinsa met its primary endpoint of progression-free survival in a phase 3 study evaluating the drug as a potential treatment in combination with rituximab for mantle cell lymphoma.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.1%, while the Vanguard Industrials Index Fund (VIS) gained 0.5% and the iShares US Industrials ETF (IYJ) was inactive.Hafnia (HAFN) stock was down more than 1% before the opening bell after the company said that Mikael Skov will step down as chief executive officer, effective Sept. 1, and be succeeded by head of asset management Soren Jensen.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.1%, and the iShares US Technology ETF (IYW) was fractionally higher, and the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased 0.4%, while the iShares Semiconductor ETF (SOXX) rose 0.1%.Super Micro Computer (SMCI) shares were up 0.9% in premarket activity following an 8.1% drop at the prior close. The Financial Times reported that the company is cooperating with Taiwanese authorities after investigators searched its Taiwan office as part of a probe into suspected exports of Nvidia (NVDA) artificial intelligence servers to China in violation of trade restrictions. Nvidia stock was 0.7% higher.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.2%.Equinor (EQNR) stock was up 0.7% before market open after the company and Var Energi agreed to exchange natural gas assets on the Norwegian continental shelf.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.6% to $71.20 per barrel on the New York Mercantile Exchange. Natural gas advanced by 2.1% to $3.25 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 1.1%, while the United States Natural Gas Fund (UNG) was 3.3% higher.Gold futures for July were up by 0.2% to $4,045.30 an ounce on the Comex. Silver futures gained by 1.3% to $59.37 an ounce. SPDR Gold Shares (GLD) advanced by 0.1%, and the iShares Silver Trust (SLV) was 0.6% higher.

Sector Update: Healthcare Stocks Advance Pre-Bell Friday

Healthcare stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) up 0.3%.BeOne Medicines (ONC) stock was up more than 1% after the company said new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed "durable responses" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.BioCryst Pharmaceuticals' (BCRX) Orladeyo was associated with "early and sustained reductions" in hereditary angioedema or HAE attacks, demonstrated by new clinical data from the ongoing APeX-P study, the company said. BioCryst Pharmaceuticals shares were up 0.1% premarket.Rocket Pharmaceuticals (RCKT) stock was up nearly 2% after the company closed the $180 million sale of its rare pediatric disease priority review voucher.

Sector Update: Healthcare

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) down 0.1%.BeOne Medicines (ONC) stock was up 1.8% after the company said new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed "durable responses" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.

BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says

BeOne Medicines (ONC) reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented "promising" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035."While more data, and in some cases, optimization is still needed, we think the company's commitment to phase 3 trials and initial data is worth paying attention to," the analyst added.RBC raised its price target on BeOne Medicines to $436 from $425 while keeping its outperform rating.Price: $276.76, Change: $-2.92, Percent Change: -1.04%

BeOne Gets FDA Approval for Beqalzi to Treat Mantle Cell Lymphoma

BeOne Medicines (ONC) said Wednesday the US Food and Drug Administration has granted accelerated approval to Beqalzi for the treatment of adults with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy.The company said continued approval for this indication is contingent upon confirmation of clinical benefit in the confirmatory trial, which is underway.Price: $317.94, Change: $+2.87, Percent Change: +0.91%

Wells Fargo Initiates Coverage on BeOne Medicines AG With Overweight Rating

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

BeOne Medicines' (ONC) supplemental biologics license application for Tevimbra, in combination with Ziihera and chemotherapy, was granted priority review designation by the US Food and Drug Administration, the company said Wednesday.This drug is for patients with a specific type of stomach or throat cancer that has spread or cannot be removed by surgery. It specifically targets tumors that test positive for a protein called HER2, which helps the cancer grow.Interim data from a phase 3 trial of the combination therapy supported the application, with the Tevimbra combination demonstrating statistically significant improvement in overall survival and progression-free survival, the company said.The combination therapy's safety findings in the trial were generally consistent with the component's known effects, BeOne Medicines added.Price: $296.42, Change: $-1.74, Percent Change: -0.58%